New Insights Into Corneal Endothelial Regeneration

Jafri, Mansab; Colby, Kathryn

doi:10.1007/s40135-019-00197-x

Cited by 3 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Rho kinase inhibitors (ROCK inhibitors) have been developed for use in ophthalmology for the treatment of glaucoma 2 , 3 and for corneal endothelium disorders. 4 , 5 The applicability of ROCK inhibitors is also being examined for conditions such as retinal diseases. 6 The effectiveness of ROCK inhibitors for corneal endothelium protection has been established in fields such as regenerative medicine, in which human corneal endothelial cell injection with a ROCK inhibitor was able to treat bullous keratopathy (BK) without conventional keratoplasty.…”

Section: Introductionmentioning

confidence: 99%

The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery

Fujimoto

Setoguchi

Kiryu

2021

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose In the field of regenerative medicine, Rho kinase inhibitors (ROCK inhibitors) show a protective effect on the corneal endothelium and promote effective healing in acute surgical wounds. In this study, we investigated the effectiveness of eyedrops containing ripasudil, a ROCK inhibitor approved in Japan for therapeutic use for glaucoma. Methods In this retrospective observational study, 13 glaucoma patients (16 eyes) were treated with 0.4% ripasudil eyedrops twice a day after cataract surgery. The control group comprised 13 patients (17 eyes). The averaged corneal endothelial cell density from one central and four paracentral points was <1500/mm 2 (range, 527 to 1439/mm 2 ). Results The mean rate of increase in the thinnest corneal thickness one week after surgery was 1.25% in the ripasudil group, which was significantly lower than the 5.97% increase observed in the control group ( P = 0.0037). The mean endothelial cell density loss 90 to 120 days after surgery, excluding bullous keratopathy patients for whom measurements were not possible was −4.5% in the ripasudil group, which was significantly lower than in control group (14.1%; P = 0.0003). Conclusions The results suggest that ripasudil may help maintain corneal endothelial functional integrity and reduce cell loss after cataract surgery in patients with low corneal endothelial cell density, suggesting that it may be more broadly useful for protection of the corneal endothelium after intraocular surgery. Translational Relevance The clinically approved ROCK inhibitor ripasudil formulated as an eye drop for glaucoma has a corneal endothelial protective effect in cataract surgery for patients with low corneal endothelial cell density.

show abstract

Section: Introductionmentioning

confidence: 99%

The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery

Fujimoto

Setoguchi

Kiryu

2021

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

show abstract

“…For example, a subpopulation of adult corneal endothelial cells from both normal and diseased tissues was recently shown to express the transcription profile of neural crest-derived progenitor cells, suggesting the local presence of cells with the potential for proliferation and differentiation. [ 7 ] The evidence for corneal endothelial regeneration is extensively summarized in recent reviews[ 8 9 ] and will not be revisited here.…”

Section: Introduction – a Historical Perspective On Endothelial Keratoplastymentioning

confidence: 99%

Regenerative medicine in Fuchs' endothelial corneal dystrophy

Yuan

Pineda

2021

Taiwan Journal of Ophthalmology

View full text Add to dashboard Cite

The management of Fuchs' endothelial corneal dystrophy (FECD) has evolved rapidly since the introduction of endothelial keratoplasty (EK). In recent years, advances in our understanding of endothelial cell biology, in particular with respect to the regenerative capacity of endothelial cells, have opened the door to novel therapeutic options that stray from the traditional paradigm of allograft transplantation. We review the development of descemetorhexis without EK (DWEK) as a primary treatment for FECD and discuss the lessons learned to date about the mechanism of wound healing, surgical technique, patient selection, and refractive outcomes. Multiple randomized clinical trials are currently underway to evaluate the potential for pharmacological supplementation with rho-associated kinase inhibitors to increase the success rate of corneal clearance following DWEK. Biologic supplementation with intracameral endothelial cell injection and acellular Descemet's membrane transplantation are other avenues of adjuvant therapy. DWEK is a promising surgical option for management of a subset of FECD patients.

show abstract

Fuchs Endothelial Corneal Dystrophy: Rethinking an Old Disease with Insights from the Laboratory and Clinical Practice

Kocaba

Colby

2019

Foundations of Corneal Disease

View full text Add to dashboard Cite

New Insights Into Corneal Endothelial Regeneration

Cited by 3 publications

References 61 publications

The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery

The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery

Regenerative medicine in Fuchs' endothelial corneal dystrophy

Fuchs Endothelial Corneal Dystrophy: Rethinking an Old Disease with Insights from the Laboratory and Clinical Practice

Contact Info

Product

Resources

About